EPO and coronary artery disorder: A sub-analysis of EMPA-HEART CardioLink-6 (Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes) randomized clinical trial, including 82 patients with DM and coronary artery disease showed that the administration of empagliflozin was associated with an increase in the EPO levels, a change in the morphology of RBCs (increase in RDW), a decrease in ferritin reserves and an increase in Ht concluding that SGLT-2i induce hematopoiesis through the increase in the secretion of EPO (15).